M
IMMX icon

Murchinson’s Immix Biopharma IMMX Stock Holding History

Murchinson’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-67,200
Closed -$154K – 50
2022
Q4 		$154K Buy
+67,200
New +$89.6K 0.02% 37
2022
Q1 		– Sell
-695,600
Closed -$2.48M – 123
2021
Q4 		$2.48M Buy
+695,600
New +$2.38M 0.24% 40

Other funds holding IMMX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UB
UMB Bank Kansas City, Missouri $7.9B AUM 29.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MAWA
Moss Adams Wealth Advisors Seattle, Washington $1.6B AUM 28.24% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
ICG
InterOcean Capital Group Nashville, Tennessee $4.19B AUM 26.29% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $92.6M AUM 41.64% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Murchinson's IMMX Position: Q1 2023 in Review

Murchinson sold out of Immix Biopharma (IMMX) in Q1 2023, closing a stake of 67,200 shares — an estimated $154K sold.

Murchinson first reported a position in IMMX in Q4 2021 and held it in 2 quarters. The position peaked at $2.48M in Q4 2021. 12 funds tracked by Wall St. Rank hold IMMX as of Q1 2023.

  • Murchinson reported no remaining Immix Biopharma position as of Q1 2023 after selling out during the quarter.
  • Murchinson sold 67,200 Immix Biopharma shares in Q1 2023, an estimated $154K.
  • Murchinson first reported a position in Immix Biopharma in Q4 2021 and held it in 2 quarters.
  • Murchinson's Immix Biopharma position peaked at $2.48M in Q4 2021.
  • 12 funds tracked by Wall St. Rank held Immix Biopharma as of Q1 2023.

Based on Murchinson's 13F filing for Q1 2023, filed 15 May 2023.